BPC-157 and TB-500 dominate the tissue-repair peptide research literature. They are routinely confused, occasionally stacked, and rarely understood in mechanistic isolation. This article compares them across mechanism, target tissue, and research applications.
Origins — they are not related
| Compound | Source | Length |
|---|---|---|
| BPC-157 | Synthetic fragment of body protection compound (gastric juice) | 15 amino acids |
| TB-500 | Synthetic fragment of thymosin beta-4 (actin sequestering) | 17 amino acids (TB4 fragment 17-23 region) |
The two peptides come from completely different parent molecules and were developed for different research lines. Both became prominent in tissue-repair literature for distinct reasons.
Mechanism — BPC-157
BPC-157’s documented mechanisms include:
- Angiogenesis via VEGFR2 upregulation
- Nitric oxide pathway modulation (bidirectional)
- FAK-paxillin signalling for fibroblast and tenocyte motility
- Growth hormone receptor expression on connective tissue cells
The primary therapeutic angle is broad system protection — gastric mucosa, tendon, ligament, muscle, gut.
Mechanism — TB-500
TB-500 (or more accurately, thymosin beta-4 and its active fragment) acts through:
- Actin sequestering — binds G-actin and prevents premature polymerisation
- Cell migration enhancement via cytoskeletal remodelling
- Endothelial cell migration and angiogenesis
- Anti-inflammatory cytokine modulation
The actin-binding action is unique among tissue-repair peptides — it directly affects cell motility at the cytoskeletal level.
Side-by-side
| Attribute | BPC-157 | TB-500 |
|---|---|---|
| Primary mechanism | Angiogenesis, NO modulation | Actin sequestering, cell migration |
| Strongest tissue evidence | Gut mucosa, tendon | Cardiac, vascular, dermal wound |
| Half-life | ~2 hours subcutaneous | ~2-3 hours subcutaneous |
| Stability (lyophilised) | Excellent | Good |
| Reconstituted shelf-life | ~4-6 weeks refrigerated | ~3-4 weeks refrigerated |
Tendon and ligament research
Both peptides feature in tendon repair research, though through different angles. BPC-157’s tendon research (Chang et al., 2014) shows acceleration of Achilles tendon-to-bone healing via growth hormone receptor expression. TB-500’s tendon research is more limited but suggests cellular migration enhancement during repair.
Cardiac and vascular research
TB-500/TB4 has stronger evidence in cardiac repair research, particularly post-myocardial-infarction models. The actin-binding mechanism appears especially relevant to cardiomyocyte recovery and vascular regeneration. BPC-157’s vascular evidence is angiogenesis-driven but less cardiac-specific.
Gut mucosa research
BPC-157 dominates gut mucosa research. Stress ulcer, NSAID damage, and inflammatory bowel disease research models all show consistent BPC-157 protection. TB-500 has not been similarly characterised in gut research.
Combination research
The two peptides target different mechanisms, so combination research is mechanistically rational. BPC-157 drives angiogenesis and NO modulation; TB-500 drives cell migration. Together, they cover more of the wound-healing cascade than either alone.
Combination research is limited but suggestive — anecdotal research reports stronger tissue-repair endpoints in animal models with combined administration. Controlled comparison trials are sparse.
When to use which in research
| Research target | Preferred peptide |
|---|---|
| Gastric/intestinal mucosa | BPC-157 |
| Tendon insertion repair | BPC-157 (stronger evidence) |
| Cardiac post-ischaemic recovery | TB-500 (stronger evidence) |
| Cell migration studies | TB-500 (direct mechanism) |
| General wound healing model | Either (or combination) |
Reconstitution notes
Both reconstitute in bacteriostatic water. BPC-157 typically at 2–5 mg/mL, TB-500 at 1–2 mg/mL. See our reconstitution protocol guide.
Chempeptides supplies both with batch CoA — see the research catalogue.
Research use only.